By continuing to use the site you agree to our Privacy & Cookies policy

New antibiotic launched for C diff

The first in a new class of antibiotics was launched in the UK last week for the treatment of Clostridium difficile infection.

Fidaxomicin (Dificlir) is manufactured by Astellas Pharma. In a statement announcing the drug’s launch, the company said fidaxomicin demonstrated a similar efficacy and safety profile to vancomycin in trials.

But fidaxomicin more than halved the rate of infection recurrence compared to vancomycin, 12.7% versus 26.9%.

Readers' comments (3)

  • hope it has a better effect on patients with c diff,and help them have a speed recovery....

    Unsuitable or offensive?

  • yes but dose it have the same side affects as vancomycin

    Unsuitable or offensive?

  • how long would it take for resistance to build up?

    Unsuitable or offensive?

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!

newsletterpromo